GFG (Global Fertility & Genetics) was founded in 2016 and is headquartered in the core of Manhattan, New York (E 57th Street), near landmarks such as Fifth Avenue and Central Park. As a high-end global assisted reproductive brand founded with Chinese investment, GFG brings together experienced U.S. reproductive specialists and focuses on providing diverse services to families worldwide, including third-generation IVF (PGT), fertility preservation (egg/sperm freezing), family building for LGBT families, and third-party reproduction.

Clinic overview GFG (Global Fertility & Genetics) was founded in 2016 and is headquartered in the core of Manhattan, New York (E 57th Street), near landmarks such as Fifth Avenue and Central Park. As a high-end global assisted reproductive brand founded with Chinese investment, GFG brings together experienced U.S. reproductive specialists and focuses on providing diverse services to families worldwide, including third-generation IVF (PGT), fertility preservation (egg/sperm freezing), family building for LGBT families, and third-party reproduction.

Core strengths Dual CAP and CLIA laboratory accreditation The laboratory is dually accredited by CAP (College of American Pathologists) and CLIA (Clinical Laboratory Improvement Amendments); only a small number of reproductive centers worldwide hold both. It uses a photocatalytic oxidation plus HEPA air-filtration system and monitors the culture environment in real time (temperature, humidity, CO2/O2) to support contamination-free embryo development.

Excellent location Located in one of New York's safer areas, combining medical care with travel convenience (major attractions such as the Empire State Building are about a 10-minute walk away).

Comprehensive service system Provides multilingual service (Chinese, English, Japanese, Spanish) and 24-hour end-to-end management, covering cross-border medical coordination between China and the U.S., legal support, and postpartum recovery guidance.

Innovative treatments Ovarian PRP therapy: injecting a patient's own platelet-rich plasma to help activate ovarian function; clinical cases have shown, for example, a 46-year-old woman's follicle count increasing from 1-2 to 6. Microfluidic sperm selection: FDA-cleared in 2018, this method mimics natural migration to select sperm with high DNA integrity, helping improve embryo health.

Equipment and technology EmbryoScope+ time-lapse monitoring: automatically captures embryo images every 5-20 minutes to build a 3D developmental record with minimal disturbance; its low-light environment mimics uterine conditions and is associated with about a 20% higher blastocyst formation rate (clinic-reported). Da Vinci robotic surgery system: precisely performs minimally invasive procedures such as endometriosis surgery and uterine scar repair, reducing tissue trauma. High-precision semen analyzer: a high-speed detection device that comprehensively analyzes sperm count, motility, morphology, and DNA fragmentation index (DFI) to optimize fertilization planning.

To learn more about multi-country assisted reproductive options, you may contact the GFG client service team for a complimentary consultation. Tel: 183-1078-7850